Everything below concerns 脂肪酸侧链. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Their 2023 song "Spleenwise" continued "the grand tradition of gothically inclined doom bands" initiated by My Dying Bride, Paradise Lost, and Type O Negative. Its composition, featuring "strong 80s overtones", unfolds at the "glacial pace" of Hangman's Chair, with stylistic echoes of the Sisters of Mercy and Tears for Fears. The guitar amplifier head that Chanut had used on previous albums had been stolen. Nostalgic for the sound they used to have and having begun playing guitar with Azzouni using an old preamplifier, Chanut decided to purchase one. However, Chanut employed Azzouni's preamp on Saddiction, as Caste had since purchased it. The group described themselves as being involved in "constant sound research". Chanut used a Bass VI to record Saddiction, an instrument he described as a cross between an electric guitar and an electric bass, which he said brought "much more consistency" to the sound. He was able to approach their music "from another prism" by changing his guitar's tuning, which boosted his creativity. "Post-punk is almost perfect ... It just needs bigger riffs", the band members said; this was the guiding principle when creating the album, noted Metal Hammer's Matt Mills. Michel Valentin of Le Parisien wrote that Saddiction is "still rooted in metal but with numerous more atmospheric, gothic, even 'cold wave' passages". On Saddiction, the band continued in the same sonic direction as on A Loner, with Toufouti mentioning experiments with chorus effects and clean tones.
=== Software code === In January 2020, Check Point Research discovered a vulnerability through which a hacker could spoof TikTok's official SMS messages and replace them with malicious links to gain access to user accounts. It was later patched by TikTok. In August 2020, The Wall Street Journal reported that TikTok tracked Android user data, including MAC addresses and IMEIs, with a tactic in violation of Google's policies. In August 2022, software engineer and security researcher Felix Krause found that in-app browsers from TikTok and other platforms contained codes for keylogger functionality but did not have the means to further investigate whether any data was tracked or recorded. TikTok said that the code is disabled.
==== Estrogen ==== Estrogens act through ERα to stimulate prolactin gene transcription directly and to promote lactotroph proliferation. ERα-knockout mice show a 10–20-fold reduction in prolactin mRNA. During pregnancy, rising estrogen levels contribute to the physiological expansion of the lactotroph population.
Sources: en.wikipedia.org
== Technical terminology == Cracking pressure Refers to the minimum pressure differential needed between the inlet and outlet of the valve at which the first indication of flow occurs (steady stream of bubbles). Cracking pressure is also known as unseating head (pressure) or opening pressure. Reseal pressure Refers to the pressure differential between the inlet and outlet of the valve during the closing process of the check valve, at which there is no visible leak rate. Reseal pressure is also known as sealing pressure, seating head (pressure) or closing pressure. Back pressure a pressure higher at the outlet of a fitting than that at the inlet or a point upstream
== External links == amylin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Amylin Nucleation Site". PDB Entry 1KUW. RCSB Protein Data Bank. doi:10.2210/pdb1kuw/pdb. Archived from the original on 16 April 2008. Retrieved 2008-05-28. Human DAP genome location and DAP gene details page in the UCSC Genome Browser. Human IAPP genome location and IAPP gene details page in the UCSC Genome Browser.
Subsequent research has found that the delayed dopaminergic phase is associated with the highly potent dopamine D4 receptor agonism of LSD's metabolite 13-hydroxy-LSD. The first phase is described as a "psychedelic experience", with "meaningfulness and portentousness" as the primary effects, while the latter phase is "clearly a paranoid state", including feeling "at the least self-centered, and usually suspicious, with ideas of reference or even paranoid convictions". The second phase typically develops about 4 to 6 hours after administration but at times up to 10 hours after administration. Parallels have been drawn between this phase and amphetamine psychosis. There is no indication that similar effects occur with other psychedelics like phenethylamines and simple tryptamines, which lack dopamine receptor agonism. The preceding findings have been described by researchers like Daniel X. Freedman and David E. Nichols.
=== Molecular Characterization === Dynamic light scattering (DLS) Matrix-assisted laser desorption/ionization (MALDI) spectrocosopy Nuclear magnetic resonance (NMR) spectroscopy Size exclusion chromatography (SEC)
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。